Timestrip PLC
21 November 2007
TIME.L
Timestrip plc
DHL successfully trial Timestrip and iStrip
Timestrip plc is pleased to announce that its Timestrip and iStrip label
technologies have been successfully trialled in a pilot project with DHL, one of
the world's leading logistics companies, to monitor temperatures of sensitive
products such as medical vaccinations during transportation.
The iStrip is a patent pending label developed by Timestrip plc which undergoes
an irreversible colour change when exposed to freezing temperatures. It is
designed to be mass-produced at low cost and to be fully integrated into the
packaging of products such as vaccines, protein based pharmaceuticals,
foodstuffs and fertilizer.
The trial was focused on improving the transportation of sensitive products in
order to ensure that the correct temperature conditions were maintained
throughout the critical storage and transportation process. Correct storage
temperatures are key to this process as up to 50% of problems with the
transportation of medical health care products for example are due to incorrect
storage temperatures.
The DHL project has successfully demonstrated the benefit of the Timestrip and
iStrip technologies, not only in monitoring optimum transport temperatures but
also in identifying, when problems do occur, which particular parts of a pallet
or shipment have been adversely affected. This allows targeted disposal of
affected products, reducing the need to destroy a product that may be scarce or
valuable.
Commenting on the trial, Mike Meakin, Quality Director, Healthcare EMEA, DHL
Exel said:
'One of the biggest challenges currently facing logistics companies is
temperature assurance in frozen, chilled and temperate conditions. It is now
clear that we can use Timestrip and iStrip labels to highlight whether a
temperature limit could have been breached. As a consequence, we have been able
to find a cost-effective way to enhance quality assurance.'
Reuben Isbitsky, Joint CEO of Timestrip plc, said:
'We are delighted to have been involved in this pilot trial with DHL that has
confirmed the unique and far-reaching benefits that our label technologies can
bring to companies transporting pharmaceutical and related healthcare products.
I look forward to being able to announce further details of developments with
DHL in the future.'
For more information, please contact:
Paul Freedman/Reuben Isbitsky, Joint CEOs, Timestrip plc 01462 440 700
Shane Dolan, Biddicks 020 7448 1000
Fergus Marcroft, Evolution Securities 020 7071 4300
This information is provided by RNS
The company news service from the London Stock Exchange